About Dihomo-gamma-linolenic Acid (DGLA)
DGLA (20:3 n-6) is an omega-6 elongation product of gamma-linolenic acid and the precursor to anti-inflammatory series-1 prostaglandins. Mechanistically interesting for inflammatory/skin conditions, but human evidence is mostly indirect (via GLA supplementation) and DGLA is rarely dosed on its own. Note the label term 'Eicosatrienoic Acid' is ambiguous: it can also mean Mead acid (20:3 n-9), which appears only in essential-fatty-acid deficiency; DGLA is the supplement-relevant compound. Grades low (mechanistic/indirect evidence only).
What Dihomo-gamma-linolenic Acid (DGLA) supports
- Precursor to anti-inflammatory series-1 prostaglandins, based mainly on mechanism and GLA studies rather than direct DGLA trials
How much Dihomo-gamma-linolenic Acid (DGLA) to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
0–0
mg
No established therapeutic dose; DGLA is usually supplied indirectly via GLA-rich oils rather than as a standalone active. Nominal range for a fatty-acid-profile line item.
Clinical evidence
Limited clinical evidence. Mechanistic/indirect (via GLA) only; label name overlaps with Mead acid.